KRAS and neoplasm: We found VRK1 expression was associated with immune-related pathways, such as myogenesis, myc-targets-V1/V2, KRAS-signaling-up, G2-checkpoint, epithelial mesenchymal-transition, E2-targets, and coagulation in most cancers, which uncovered a potential association between VRK1 expression and immune activation in the tumor microenvironment (TME).